BioCryst Pharmaceuticals (BCRX) News Today $8.56 +0.01 (+0.06%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Y Intercept Hong Kong Ltd Purchases 73,242 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)July 25 at 4:33 AM | marketbeat.comCwm LLC Increases Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)July 25 at 3:46 AM | marketbeat.comGW&K Investment Management LLC Has $21.64 Million Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)July 22 at 8:38 AM | marketbeat.comBioCryst: ORLADEYO Powers Profitability Amidst Rising HAE CompetitionJuly 21, 2025 | seekingalpha.comBioCryst Pharmaceuticals Inc (BCRX) Announces Upcoming Q2 2025 Financial Results Release | BCRX ...July 21, 2025 | gurufocus.comBioCryst to Report Second Quarter 2025 Financial Results on August 4July 21, 2025 | globenewswire.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $16.70 Consensus PT from AnalystsJuly 20, 2025 | americanbankingnews.comBrokers Issue Forecasts for BCRX Q2 EarningsJuly 19, 2025 | americanbankingnews.comHussman Strategic Advisors Inc. Buys Shares of 315,000 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)July 18, 2025 | marketbeat.comSegall Bryant & Hamill LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)July 18, 2025 | marketbeat.comQ2 Earnings Estimate for BCRX Issued By WedbushJuly 17, 2025 | marketbeat.comWedbush Has Bullish Forecast for BCRX FY2025 EarningsJuly 17, 2025 | americanbankingnews.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 17, 2025 | marketbeat.comWhat is Wedbush's Estimate for BCRX FY2025 Earnings?July 16, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Rice Hall James & Associates LLCJuly 14, 2025 | marketbeat.comRBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13July 11, 2025 | finance.yahoo.comBioCryst to Highlight Patient-focused Research at the 2025 US HAEA National SummitJuly 9, 2025 | globenewswire.comIs BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? - NasdaqJuly 8, 2025 | nasdaq.comBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate DevelopmentJuly 7, 2025 | finanznachrichten.deBioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate DevelopmentJuly 7, 2025 | globenewswire.comBioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264MJuly 6, 2025 | msn.comBCRX - BioCryst Pharmaceuticals Inc Price vs Fair Value - MorningstarJuly 3, 2025 | morningstar.comMWedbush Issues Positive Estimate for BCRX EarningsJuly 3, 2025 | marketbeat.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comWedbush Issues Positive Outlook for BCRX EarningsJuly 2, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $15.00July 1, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Outlook for BCRX EarningsJuly 1, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 4.5% - What's Next?June 30, 2025 | marketbeat.comBioCryst Pharmaceuticals' (BCRX) Outperform Rating Reiterated at Royal Bank Of CanadaJune 30, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Wedbush Analyst SaysJune 30, 2025 | marketbeat.comBioCryst Pharmaceuticals is Now Oversold (BCRX) - NasdaqJune 29, 2025 | nasdaq.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Lowered by Wall Street ZenJune 28, 2025 | marketbeat.comBioCryst to Sell European Orladeyo Business for Up to $264 MillionJune 27, 2025 | marketwatch.comBioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock? - NasdaqJune 27, 2025 | nasdaq.comBioCryst sells European Orladeyo business in $264M dealJune 27, 2025 | bizjournals.comBioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays BearishJune 27, 2025 | msn.comBioCryst to sell European Orladeyo business for up to $264MJune 27, 2025 | msn.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Time to Buy?June 27, 2025 | marketbeat.comBioCryst Pharmaceuticals (BCRX) Projects Strong Cash Position by 2027 | BCRX Stock NewsJune 27, 2025 | gurufocus.comBioCryst Pharmaceuticals (BCRX) to Divest European Orladeyo Business for $264MJune 27, 2025 | gurufocus.comBioCryst Sells European ORLADEYO Business for $264MJune 27, 2025 | tipranks.comBioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 MillionJune 27, 2025 | globenewswire.comBCRX BioCryst Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Receives Buy Rating from Needham & Company LLCJune 25, 2025 | marketbeat.comBioCryst Pharmaceuticals Inc (BCRX) Announces Promising Long-term Data for ORLADEYO in HAE ...June 16, 2025 | gurufocus.comBioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACIJune 16, 2025 | globenewswire.comORLADEYO® (berotralstat) Approved in ColombiaJune 13, 2025 | globenewswire.comCantor Fitzgerald Weighs in on BCRX FY2026 EarningsJune 10, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European CountriesJune 7, 2025 | finanznachrichten.deBioCryst Achieves Reimbursement for ORLADEYO Across all Major European CountriesJune 6, 2025 | globenewswire.com Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Media Mentions By Week BCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼0.921.05▲Average Medical News Sentiment BCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼107▲BCRX Articles Average Week Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HALO News Today IONS News Today RGEN News Today ALKS News Today LGND News Today FOLD News Today CLDX News Today DVAX News Today INVA News Today NVAX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
